PCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pacira Biosciences Inc (PCRX) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the stock has some positive catalysts, such as hedge fund buying and easing pricing headwinds in the sector, the financial performance shows significant declines in net income and EPS. Additionally, insider selling and the lack of strong technical or proprietary trading signals make this stock less compelling for immediate investment.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 58.953, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its pivot level of 21.02, with resistance at 21.842 and support at 20.199.
Hedge funds are significantly increasing their buying activity (+695.83% last quarter). Analysts see easing pricing headwinds and opportunities for innovation and margin expansion in the specialty pharmaceuticals sector. The NOPAIN Act is expected to enhance access to key surgical procedures for Pacira's products.
Insiders are heavily selling (+928.27% last month). Financial performance in Q3 2025 shows a sharp decline in net income (-103.79% YoY) and EPS (-103.86% YoY). No recent news or significant events to drive short-term momentum.
In Q3 2025, revenue increased by 6.49% YoY to $179.5M, and gross margin improved to 72.93% (+6.54% YoY). However, net income dropped significantly to $5.43M (-103.79% YoY), and EPS fell to 0.12 (-103.86% YoY), indicating profitability challenges.
Barclays initiated coverage with an Equal Weight rating and a $27 price target, citing a neutral view on the specialty pharmaceuticals sector but noting improving investor sentiment. H.C. Wainwright assumed coverage with a Buy rating and a $38 price target, highlighting the positive impact of the NOPAIN Act and approval for nerve blocks.
